Original Research
Accepted on 14 Nov 2025
A CD47 Antibody with Minimized Erythrocyte and Thrombocyte Toxicities
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
Type at least 3 characters
1,538 articles
Original Research
Published on 14 Nov 2025
Phytochemical and nanoparticle-based therapeutic potential of Sphaeranthus indicus against hepatocellular carcinoma via cryptomeridiol targeting
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1691905
- 330 views
Mini Review
Accepted on 13 Nov 2025
Myeloid-Driven Immunosuppression in Head and Neck Cancer: Single-Cell ATAC/RNA and Spatial Transcriptomic Perspectives
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
- 135 views
Brief Research Report
Accepted on 13 Nov 2025
Exploratory Spatial Transcriptomic Profiling of Peritumoral Th2 Immune Polarization in HPV-Positive Oropharyngeal Cancer
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
Original Research
Published on 13 Nov 2025
Adjuvant tyrosine kinase inhibitors plus anti-PD-1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1710602
- 1,391 views
Case Report
Accepted on 12 Nov 2025
Malignant Mesothelioma in Rare Sites: Two Case Reports
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
Mini Review
Accepted on 12 Nov 2025
Immunocytokines in Cancer Immunotherapy: Opportunities and Challenges
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
Case Report
Published on 12 Nov 2025
Case Report: Accelerated parathyroid adenoma progression and hypercalcemia-driven neurotoxicity following pembrolizumab-based neoadjuvant therapy in triple-negative breast cancer: a case of multisystem immune-related adverse events
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1607957
- 307 views
Original Research
Published on 10 Nov 2025
A bibliometric visualization of resistance to lung cancer immunotherapy: a decade of research progress (2014–2024)
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1656967
- 571 views
Review
Published on 10 Nov 2025
Rewiring tumor visibility: The immunopeptidome as a dynamic interface between antigen processing, microenvironmental stress, and immune recognition
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1691719
- 518 views
Original Research
Accepted on 07 Nov 2025
The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
- 134 views
Case Report
Accepted on 07 Nov 2025
Sintilimab Combined with Chemotherapy in Advanced Pulmonary Epithelioid Hemangioendothelioma: A Case Report and Translational Insights
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
Original Research
Published on 07 Nov 2025
Cutaneous adverse events associated with the efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1689519
- 601 views
Original Research
Published on 07 Nov 2025
Association between immune-related adverse events and recurrence dynamics under adjuvant anti–PD-1 therapy in resected melanoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1671315
- 373 views
Original Research
Accepted on 06 Nov 2025
Serum Autoantibody Profiles in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Cross-Sectional Study
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
Correction
Accepted on 06 Nov 2025
Correction: Case report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
- 105 views